5-HT2A antagonists

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference

Retrieved on: 
Thursday, June 10, 2021
Data management, Chemical compounds, 5-HT2A antagonists, Antipsychotics, Ketones, Organofluorides, Piperidines, Roluperidone, NERV, NASDAQ, Schizophrenia, JMP

WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual JMP Securities Life Sciences Conference on June 16, 2021 at 10:00 a.m. Eastern Time.

Key Points: 
  • WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual JMP Securities Life Sciences Conference on June 16, 2021 at 10:00 a.m. Eastern Time.
  • The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Companys web site, http://ir.minervaneurosciences.com .
  • Minervas portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinsons disease.
  • Minervas common stock is listed on the NASDAQ Global Market under the symbol NERV.For more information, please visit www.minervaneurosciences.com .

Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference

Retrieved on: 
Friday, May 28, 2021
Chemical compounds, 5-HT2A antagonists, Antipsychotics, Ketones, Organofluorides, Piperidines, Roluperidone, NERV, Schizophrenia, Chemistry

WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021 at 11:00 a.m. Eastern Time.

Key Points: 
  • WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021 at 11:00 a.m. Eastern Time.
  • The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Companys web site, http://ir.minervaneurosciences.com .
  • Minervas portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinsons disease.
  • Minervas common stock is listed on the NASDAQ Global Market under the symbol NERV.For more information, please visit www.minervaneurosciences.com .

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors

Retrieved on: 
Tuesday, April 27, 2021
Legal, Professional services, Psychiatry, Organic compounds, Chemical compounds, Atypical antipsychotics, Acadia Pharmaceuticals, 5-HT2A antagonists, Pimavanserin, Psychosis, Dementia

b'The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Acadia Pharmaceuticals Inc. (\xe2\x80\x9cAcadia\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) (NASDAQ: ACAD ) securities between June 15, 2020 and April 4, 2021, inclusive (the \xe2\x80\x9cClass Period\xe2\x80\x9d).

Key Points: 
  • b'The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Acadia Pharmaceuticals Inc. (\xe2\x80\x9cAcadia\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) (NASDAQ: ACAD ) securities between June 15, 2020 and April 4, 2021, inclusive (the \xe2\x80\x9cClass Period\xe2\x80\x9d).
  • Acadia investors have until June 18, 2021 to file a lead plaintiff motion.\nIf you are a shareholder who suffered a loss, click here to participate.\nAcadia is a biopharmaceutical company that develops a drug called pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as an adjunctive treatment for major depressive disorder.
  • To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.
  • If you inquire by email please include your mailing address, telephone number, and number of shares purchased.\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210427005057/en/\n'

Otsuka and Lundbeck Announce Decision to Continue Phase III Clinical Trial Evaluating Brexpiprazole for Treatment of Agitation in Patients With Alzheimer's-type Dementia

Retrieved on: 
Tuesday, April 13, 2021
Pharmaceutical, Health, Clinical trials, Serotonin antagonists, Atypical antipsychotics, 5-HT2A antagonists, Otsuka Pharmaceutical, Brexpiprazole, Lundbeck, Dementia, Agitation, the study, brexpiprazole, Otsuka Pharmaceutical, H. Lundbeck A/S

b"Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announce the decision to continue the recruitment of patients in the phase III clinical trial of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type (NCT03548584).

Key Points: 
  • b"Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announce the decision to continue the recruitment of patients in the phase III clinical trial of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type (NCT03548584).
  • Completion of the trial is expected in the first half of 2022.\nTrial 331-14-213 (NCT03548584; Trial 213) was designed to assess the safety, tolerability and efficacy of brexpiprazole in the treatment of patients with agitation in Alzheimer\xe2\x80\x99s dementia.
  • Patients participating in the trial are from countries including Bulgaria, Hungary, Serbia, Slovakia, Spain, Ukraine, and the U.S.
  • In Europe, brexpiprazole is distributed and marketed under the brand name Rxulti\xc2\xae.\nBrexpiprazole was discovered by Otsuka and is being co-developed by Otsuka and Lundbeck.

Pimavanserin: A Selective Serotonin Inverse Agonist and Antagonist Preferentially Targeting 5-HT2A Receptors - Global Emerging Insights and Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 10, 2021
Health, Pharmaceutical, Branches of biology, Chemical compounds, Organic compounds, Piperidines, Atypical antipsychotics, 5-HT2A antagonists, Pimavanserin, Ureas, 5-HT2A receptor, Serotonin, Psychosis, Agonist

The "Pimavanserin - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pimavanserin - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors.
  • These receptors are thought to play an important role in psychosis, schizophrenia, depression and other neuropsychiatric disorders.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Minerva Neurosciences to Present at Jefferies Virtual London Healthcare Conference

Retrieved on: 
Monday, November 9, 2020
Psychoactive drugs, Antidepressants, Hypnotics, Seltorexant, Chemical compounds, 5-HT2A antagonists, Drugs, Roluperidone

WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual London Healthcare Conference on November 17, 2020 at 12:55 p.m. GMT (7:55 a.m. EST).

Key Points: 
  • WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual London Healthcare Conference on November 17, 2020 at 12:55 p.m. GMT (7:55 a.m. EST).
  • The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Companys web site, http://ir.minervaneurosciences.com .
  • Minervas portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinsons disease.
  • Minervas common stock is listed on the NASDAQ Global Market under the symbol NERV.For more information, please visit www.minervaneurosciences.com .

Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Retrieved on: 
Monday, October 26, 2020
Mental health, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Psychiatric diagnosis, Psychiatry, Aging-associated diseases, Chemical compounds, Organic compounds, Acadia Pharmaceuticals, 5-HT2A antagonists, Piperidines, Cognitive disorders, Pimavanserin, Dementia, Psychosis, Pimavanserin, Acadia Pharmaceuticals

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-related psychosis and neurodegenerative diseases will be shared at the 13th Clinical Trials on Alzheimer's Disease Conference (CTAD), being held virtually November 4-7, 2020.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-related psychosis and neurodegenerative diseases will be shared at the 13th Clinical Trials on Alzheimer's Disease Conference (CTAD), being held virtually November 4-7, 2020.
  • Scientific presentations include those investigating pimavanserin treatment and its impact on cognition and motor function in patients with neuropsychiatric symptoms related to neurodegenerative diseases, including dementia-related psychosis.
  • CTAD Accepted Scientific Presentations include:
    Oral Presentation (OC31): Impact of Pimavanserin on Cognitive Measures in Patients with Neurodegenerative Disease: Results from 4 Placebo-Controlled Clinical Studies on Friday, November 6, 10:45 11:00 a.m.
  • Presenting author: Mona Darwish, Acadia Pharmaceuticals Inc.
    Poster Presentation (P75): Impact of Pimavanserin Treatment on Motor Function in Patients with Neurodegenerative Disease: Results from 3 Clinical Studies.

Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience

Retrieved on: 
Monday, September 14, 2020
Drugs, Receptor antagonists, Psychoactive drugs, Opioid antagonists, Atypical antipsychotics, Muscarinic antagonists, RTT, 5-HT2A antagonists, Olanzapine/samidorphan, Alkermes, Samidorphan, ALKS

DUBLIN, Sept. 14, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new real-world outcomes research and clinical data related to its psychiatry portfolio at thePsych Congress 2020 Virtual Experience, held Sept. 10-13, 2020.

Key Points: 
  • DUBLIN, Sept. 14, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new real-world outcomes research and clinical data related to its psychiatry portfolio at thePsych Congress 2020 Virtual Experience, held Sept. 10-13, 2020.
  • "We were pleased to share new research at this year's virtual Psych Congress, underscoring Alkermes' commitment to addressing the challenges faced by those living with serious mental illness," saidAmy O'Sullivan, Vice President, Health Economics and Outcomes Research at Alkermes.
  • In addition to the outcomes data, Alkermes presented several posters related to the company's psychiatry products and development candidates, ARISTADA(aripiprazole lauroxil), ARISTADA INITIO(aripiprazole lauroxil) and ALKS 3831 (olanzapine/samidorphan).
  • Alkermes plcis a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology.

Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience

Retrieved on: 
Monday, September 14, 2020
Drugs, Receptor antagonists, Psychoactive drugs, Opioid antagonists, Atypical antipsychotics, Muscarinic antagonists, RTT, 5-HT2A antagonists, Olanzapine/samidorphan, Alkermes, Samidorphan, ALKS

DUBLIN, Sept. 14, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new real-world outcomes research and clinical data related to its psychiatry portfolio at thePsych Congress 2020 Virtual Experience, held Sept. 10-13, 2020.

Key Points: 
  • DUBLIN, Sept. 14, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new real-world outcomes research and clinical data related to its psychiatry portfolio at thePsych Congress 2020 Virtual Experience, held Sept. 10-13, 2020.
  • "We were pleased to share new research at this year's virtual Psych Congress, underscoring Alkermes' commitment to addressing the challenges faced by those living with serious mental illness," saidAmy O'Sullivan, Vice President, Health Economics and Outcomes Research at Alkermes.
  • In addition to the outcomes data, Alkermes presented several posters related to the company's psychiatry products and development candidates, ARISTADA(aripiprazole lauroxil), ARISTADA INITIO(aripiprazole lauroxil) and ALKS 3831 (olanzapine/samidorphan).
  • Alkermes plcis a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology.

Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Retrieved on: 
Wednesday, September 9, 2020
Psychoactive drugs, Antidepressants, Drugs, Hypnotics, Seltorexant, 5-HT2A antagonists, Roluperidone, Insomnia

WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020 at 10:00 a.m. Eastern Time.

Key Points: 
  • WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020 at 10:00 a.m. Eastern Time.
  • The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Companys web site, http://ir.minervaneurosciences.com .
  • Minervas portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinsons disease.
  • Minervas common stock is listed on the NASDAQ Global Market under the symbol NERV.For more information, please visit www.minervaneurosciences.com .